New program aims to improve dental care in schizophrenia patients
NCT ID NCT02512367
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a dental health education program for people with schizophrenia to see if it could improve their oral hygiene and quality of life. Participants were randomly assigned to either the education program or standard monitoring. The study lasted 12 months and included dental check-ups at the start, 6 months, and 12 months. Unfortunately, the trial was terminated early, so the results are limited.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Dental care education program
- What this could lead to
- If successful, this program could help people with schizophrenia maintain better dental health and improve their overall well-being.
- What could go wrong
- The trial was terminated early with only 79 participants, so results are limited and may not be reliable. The program may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
79 people
The number who actually took part.
- Started
-
Apr 2017
- Finished
-
Oct 2020
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with a confirmed diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM V) * Managed at a specialized establishment * Older than 18 years. * who have provided written informed consent to take part in the study Exclusion Criteria: * Fully hospitalized patients * Patients who are unstable from a psychiatric poit of view or who suffer from delirium. * Subjects with less than one incisor, canine, premolar and molar on each hemi-arch * Patients with a risk of infectious endocarditis or a major risk of superinfection * Patients on long-term treatment with antibiotics (Impact of antibiotherapy on oral flora) * Patients treated with chemotherapy * Pregnant or breastfeeding women * Patients without National Health Insurance cover. * Poor written and/or oral comprehension of the French language
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Schizophrenia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CH Esquirol
Limoges, 87025, France
-
CH La Chartreuse
Dijon, 21000, France
-
CH Le Vinatier
Bron, 69678, France
-
CH de Jury
Metz, 57073, France
-
CH de Novillars
Novillars, 25220, France
-
CH de Saint-Rémy et Nord Franche Comté
Saint-Rémy, 70160, France
-
CH de Semur en Auxois
Semur-en-Auxois, 21140, France
-
CHS de la Savoie
Chambéry, 73011, France
-
CHS du Jura
Dole, 39108, France
-
CHU de Besançon
Besançon, 25000, France
-
CHU de DIJON
Dijon, 21079, France
-
Chs Epsan
Brumath, 67173, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug
- A shot every few weeks? new drug tested for schizophrenia